Overview
Pancreatic cancer is the fifth leading cause of cancer death in Western nations, with rising incidence globally. Pancreatic ductal adenocarcinoma (PDAC) accounts for over 90% of cases. Five-year survival remains approximately 12%, owing to late-stage diagnosis, aggressive biology, and therapeutic resistance. Risk factors include obesity, type 2 diabetes, chronic pancreatitis, smoking, and periodontal disease. The convergence of metallomics, microbiome, and metabolomic evidence now positions pancreatic cancer as a paradigm case for multi-omic biomarker discovery within the gut metal microbiome axis.
Metallomic Signature
The landmark study by Schilling et al. (2020) demonstrated that a combined urinary panel of Ca, Mg, Zn, and Cu achieves AUC 0.99 (sensitivity 95.2%, specificity 97.8%) for PDAC detection — among the highest metallomic diagnostic performances reported for any cancer.
| Metal | Direction | Key Evidence | |
|---|---|---|---|
| **[[copper | Cu]]** | Elevated (urine, serum) | ATP7A overexpression in PDAC; Cu increased across cancer types as a near-universal biomarker |
| **[[zinc | Zn]]** | Elevated (urine), depleted (tissue) | Disrupted ZnT/ZIP transporters (ZIP3, SLC30A); Zn isotope fractionation as novel biomarker |
| Ca | Decreased (urine) | S100 protein dysregulation; AUC 0.796 individually | |
| Mg | Decreased (urine) | Disrupted cell proliferation and protein synthesis; AUC 0.783 individually | |
| **[[cadmium | Cd]]** | Elevated | Zhang 2022 review confirms Cd increase in pancreatic cancer tissue |
| Se | Depleted | Impaired selenoprotein antioxidant defense |
Zinc isotope fractionation represents a novel biomarker dimension: PDAC patients excrete isotopically light Zn (median delta-66/64-Zn = -0.15 per mille vs +0.02 in controls, p=0.002), reflecting metalloprotein dysregulation. The healthy Zn concentration-to-Cu ratio correlation (r2=0.66) is completely abolished in PDAC (r2=0.0002), indicating fundamental disruption of metal homeostasis relevant to metal carcinogenesis and oxidative stress.
Tumor Microbiome
PDAC tumors harbor intratumoral bacteria, confirmed by 16S rRNA FISH and LPS immunohistochemistry. Gammaproteobacteria dominate, with Pseudomonas as the predominant genus. Tumor microbiome composition varies by PDAC molecular subtype: basal-like tumors are enriched in Acinetobacter, Pseudomonas, and Sphingopyxis, predicting significantly worse survival. Bacterial CDD (cytidine deaminase) enzyme metabolizes gemcitabine into its inactive form, mediating chemotherapy resistance — a direct mechanism linking dysbiosis to treatment failure.
Oral Microbiome Connection
The JAMA Oncology study by Meng et al. (2025) — a nested case-control within 122,000 individuals (445 PC cases, median 8.8-year follow-up) — established the oral microbiome as a prospective predictor of pancreatic cancer. A microbial risk score (MRS) combining 27 bacterial and fungal species conferred 3.44-fold increased PC risk per 1-SD increase (95% CI 2.63-4.51). Key pathogens include P. gingivalis, E. nodatum, P. micra (red/orange complex periodontal pathogens), and Candida tropicalis. This oral-pancreatic axis may operate through hematogenous or biliary translocation of pathobionts and their inflammatory mediators.
Gut Microbiome
Gut dysbiosis drives pancreatic carcinogenesis through persistent low-grade inflammation. LPS from Gram-negative bacteria activates NF-kB and MAPK signaling, while SCFA imbalance removes protective anti-inflammatory signals. bile acid metabolism alterations are central: deoxycholic acid promotes DNA damage via EGFR ligand amphiregulin. Obesity and type 2 diabetes — both established PC risk factors — converge on gut dysbiosis with decreased microbial diversity, increased Firmicutes/Bacteroidetes ratio, and procarcinogenic metabolite production.
Mendelian Randomization Evidence
Two-sample MR studies provide causal evidence for microbiome-PC relationships. Jiang et al. (2023) identified Senegalimassilia as protective (OR 0.635) and Odoribacter (OR 1.899), Streptococcus (OR 1.712), and Ruminiclostridium9 (OR 1.976) as risk-increasing. Daniel et al. (2024) — the largest MR study to date (8,769 cases) — found mannitol (OR 0.97) and methionine (OR 0.97) as causally protective metabolites, while carnitine and hippuric acid increased risk. Romboutsia (OR 0.87) was confirmed as protective across multiple sensitivity analyses.
Mycobiome
Oral and gut fungal communities are markedly altered in PDAC. Aspergillus achieves AUC 0.983 as a salivary biomarker for PDAC, with Cladosporium at AUC 0.969. PDAC patients show dramatically expanded oral fungal diversity (5,022 vs 830 OTUs) with decreased Shannon diversity. In acute pancreatitis — a PC precursor — Candida dominates the fecal mycobiome at 61%, with Aspergillus-WBC correlations suggesting fungal-driven inflammatory amplification. These findings from the gut metal microbiome framework connect fungal iron dependence to metal-driven mycobiome shifts.
Metabolomics
Serum metabolomics achieves AUC 0.93 for PC detection using four metabolites (xylitol, 1,5-anhydro-D-glucitol, histidine, inositol), outperforming CA19-9 in early-stage disease (sensitivity 77.8% vs 55.6%). Amino acid metabolism is profoundly disrupted in PDAC tumors: BCAAs (leucine, isoleucine, valine) sustain PDAC growth by fueling lipogenesis through BCAT2/BCKDHA, independent of glycolysis. Intratumoral metabolomics identifies 298 significantly altered metabolites, with amino acid dipeptides and arginine metabolism pathways most dysregulated — correlating with Pseudomonas abundance.
Virome
Gut virome composition predicts immunotherapy response with AUC 0.768 (outperforming bacterium-only models at AUC 0.664). Responder-enriched bacteriophages target Faecalibacterium and Roseburia (SCFA producers), while non-responder phages target Clostridium and Bacteroides. Phage-based therapeutic peptides targeting PDAC represent an emerging strategy.
Diet and Risk Factors
Obesity increases PC risk (meta-analysis by Berrington et al. 2003), and diabetes confers significant additional risk (Huxley et al. 2005 meta-analysis: RR 1.82). Dietary fiber is protective (Wang et al. 2015 meta-analysis). Polyphenols — particularly quercetin — inhibit pancreatic cancer stem cell self-renewal and attenuate sonic hedgehog and beta-catenin signaling. These dietary factors operate partly through modulation of the gut metal microbiome and bile acid metabolism.
Therapeutics
- Probiotics: Ferrichrome from Lactobacillus casei induces p53-mediated apoptosis in PDAC cells including 5-FU-resistant lines; 10 mg/kg reduces xenograft tumor volume significantly. Connects to iron biology through siderophore-mediated metal chelation and ferroptosis pathways.
- Synbiotics RCT: Maher et al. (2024) demonstrated synbiotics (probiotics + inulin) elevated CD8+ T cells to 61.5% (vs 15.8% placebo) and reduced postoperative bacteremia in a 90-patient RCT (NCT06199752).
- FMT: Fecal microbiota transplantation from long-term PDAC survivors enhances anti-tumor immunity in preclinical models.
- Gallium-polyphenol nanoparticles: LGG-loaded gallium-polyphenol constructs reprogram intratumoral microbiota and tumor immune microenvironment.
- Phage therapy: Phage-based peptides show selective PDAC targeting in preclinical models.